Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Leap Therapeutics To Present Updated Data From The DisTinGuish Study Of DKN-01 Plus Tislelizumab And Preclinical Data In Colorectal Cancer Models At The Society of Immunotherapy for Cancer Annual Meeting

CAMBRIDGE, Mass., Oct. 5, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be

LPTX